Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials

Khachatryan, Davit; Groll, Dianne; Booij, Linda; Sepehry, Amir Ali; Schütz, Christian

doi:10.1016/j.genhosppsych.2015.10.007

Cited by 86 publications

(42 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Selective serotonin reuptake inhibitors have shown efficacy in symptomatic relief and decreasing rates of relapse, as have norepinephrine reuptake inhibitors (37). Other drugs used to treat and resolve ancillary symptoms such as intrusion and hyperarousal include aand b-blockers (38) and, more recently, novel treatments such as ketamine (39). Considered to have strong research support by the American Psychological Association and the U.S. Department of Defense and Department of Veterans Affairs, cognitive processing therapy has been successful in reducing feelings of fear and culpability in PTSD (40).…”

Section: Ptsd: Diagnosis and Therapymentioning

confidence: 99%

Long-Term Clinical and Neuronuclear Imaging Sequelae of Cancer Therapy, Trauma, and Brain Injury

et al. 2019

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe clinical features and therapeutic approaches in the evaluation and management of cancer-and chemotherapy-related cognitive impairment (CRCI), posttraumatic stress disorder (PTSD), and traumatic brain injury (TBI); (2) discuss the role of neuroimaging in contributing to understanding of relationships between clinical features of CRCI, PTSD, and TBI, with aspects of underlying regional cerebral function; and (3) identify which brain processes are most consistently shown to be affected in CRCI, PTSD, and TBI.

show abstract

Section: Ptsd: Diagnosis and Therapymentioning

confidence: 99%

Long-Term Clinical and Neuronuclear Imaging Sequelae of Cancer Therapy, Trauma, and Brain Injury

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Prazosin is an alpha-1 noradrenergic antagonist that crosses the blood brain barrier, and that may reduce nightmares and sleep disturbances that characterize PTSD [27][28][29][30][31]. Based on the extensive review of open trials and placebo-controlled studies conducted in military veterans and civilians with nightmares PTSD, the American Academy of Sleep Medicine (AASM) recommended prazosin as an evidencebased treatment of nightmares, especially in the context of PTSD [32]; see also: [33][34][35] for recent reviews.…”

Section: Alpha-1 Noradrenergic Antagonistsmentioning

confidence: 99%

Nightmares and Posttraumatic Stress Disorder (PTSD)

Campbell

Germain

2016

Curr Sleep Medicine Rep

View full text Add to dashboard Cite

Nightmares are a unique feature of posttraumatic stress disorder (PTSD). Although nightmares are a symptom of PTSD, they have been shown to independently contribute to psychiatric distress and poor outcomes, including heightened suicidality and suicide. Nightmares are often resistant to recommended pharmacological or psychological PTSD treatments. Fortunately, nightmare-specific treatments are available, and improvements in nightmares are associated with clinically significant improvements in sleep quality and severity of daytime PTSD symptoms. The recent literature on the characteristics, neurophysiology, and treatment of nightmares in the context of PTSD is reviewed. Recent findings on the neurophysiological correlates of nightmares and more generally, dreaming, are also discussed here as they suggest novel directions for understanding the mechanisms underlying nightmares comorbid with PTSD and potential novel treatment approaches.

show abstract

“…Prazosin has been explored in the treatment of SUD and PTSD separately, but only recently in the treatment of co-occurring SUD and PTSD. Prazosin has demonstrated efficacy to reduce PTSD-related nightmares and daytime hyperarousal symptoms, and to improve sleep among individuals with PTSD [27, 78]. Among individuals with single alcohol use disorder diagnosis, prazosin has been shown to reduce alcohol consumption and reduce craving to alcohol cues [79, 80].…”

Section: Introductionmentioning

confidence: 99%

Concurrent Treatment of Substance Use and PTSD

Flanagan

Korte

Killeen

et al. 2016

Curr Psychiatry Rep

109

View full text Add to dashboard Cite

Substance use disorders (SUD) and posttraumatic stress disorder (PTSD) are chronic, debilitating conditions that frequently co-occur. Individuals with co-occurring SUD and PTSD suffer a more complicated course of treatment and less favorable treatment outcomes compared to individuals with either disorder alone. The development of effective psychosocial and pharmacological interventions for co-occurring SUD and PTSD is an active and critically important area of investigation. Several integrated psychosocial treatments for co-occurring SUD and PTSD have demonstrated promising outcomes. While recent studies examining medications to treat co-occurring SUD and PTSD have yielded encouraging findings, there remain substantial gaps in the evidence base regarding the treatment of co-occurring SUD and PTSD. This review will summarize the findings from clinical trials targeting a reduction in SUD and PTSD symptoms simultaneously. These results may improve our knowledge base and subsequently enhance our ability to develop effective interventions for this complex comorbid condition.

show abstract

Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials

Cited by 86 publications

References 46 publications

Long-Term Clinical and Neuronuclear Imaging Sequelae of Cancer Therapy, Trauma, and Brain Injury

Long-Term Clinical and Neuronuclear Imaging Sequelae of Cancer Therapy, Trauma, and Brain Injury

Nightmares and Posttraumatic Stress Disorder (PTSD)

Concurrent Treatment of Substance Use and PTSD

Contact Info

Product

Resources

About